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Abstract
Background:  To date, tools to study metastasis in endometrial cancers are insufficiently
developed. The aim of this study was to characterize the cell line EN-1078D, a new endometrial
carcinoma cell line derived from a metastasis to the ovary.
Methods and Results: Cells were characterized using cytology, transmission electron
microscopy, karyotyping and morphological appearance in culture. Molecular features were
determined by RT-PCR, Western Blot, FISH and sequencing. MTT proliferation assays were
performed to investigate the sensitivity of EN-1078D to anticancer agents such as cisplatin and
doxorubicin. Also, subcutaneous and intravenous injections in nude mice were done to test the
tumorigenic and metastatic properties of EN-1078D cells. Our results indicate that EN-1078D cells
express both oestrogen receptors isoforms (ER alpha and ER beta) and also low levels of
progesterone receptor B (PR-B). In addition, this cell line expresses high levels of MMP-2 and MMP-
14 mRNA, low levels of TIMP-1 and TIMP-2 transcripts and no detectable levels of MMP-9 mRNA.
Moreover, all nude mice developed tumors by subcutaneous injections and cell invasion was
observed in vitro in response to TGF-beta 3. Her-2/neu was not overamplified but mutations in the
C-2 domain of PTEN gene as well as codon 12 of the K-Ras gene were found. Finally, EN-1078D
shows sensitivity to drugs commonly used in chemotherapy such as cisplatin and doxorubicin: IC50
of 2.8 µM of cisplatin after 72 hours of exposure and 0.54 µM of doxorubicin after 48 hours.
Conclusion: Taken together, these results suggest that EN-1078D will be an excellent tool to
study the properties of metastatic endometrial cancer cells in vitro and their regulation by sex
steroids.
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Background
Uterine cancer is the fourth commonly diagnosed cancer
among women in the North America. Ninety-seven per-
cent of all cancers of the uterus arise from the glands of the
endometrium and are known as endometrial carcinomas
[1]. When diagnosed at early stages of the disease, this
type of cancer is a highly curable malignancy with a 5-year
relative survival rate of more than 80% [2]. However,
patients presenting metastases have a 5-year survival rate
of less than 20% [2]. Indeed, metastasis represents the
main cause of death for patients with endometrial carci-
noma. Very few models are available, to date, for the
experimental characterization of factors involved in the
metastatic phenotype in endometrial carcinoma cells.
Cell models of endometrial cancers are characterized by
particular gene expressions and mutations which stratefy
the disease. The cytokeratins (Ker) and other types of
intermediate filaments are routinely used as indicators of
tumor cell types as well as markers of differentiation [3],
because their composition in any particular epithelium is
predictable [4] The presence of functional steroid recep-
tors, estrogen receptor alpha and beta (ERα and ERβ), pro-
gesterone receptor A and B (PR-A and PR-B) has been
quantitatively associated with histologic differentiation
[5], response to therapy [6] and metastatic potential [7].
Sex steroid hormones influence the metastatic phenotype
in cancer cells, notably by regulating adhesion/de-adhe-
sion events, angiogenesis, cellular invasion into the base-
ment membrane and interstitium [8]. Therefore, the
expression levels of ER and PR, as well as the impact of sex
steroids are important regulators of endometrioid cells.
The uterus undergoes extensive tissue remodelling
throughout each reproductive cycle and these dynamics
change are regulated, in part, by the matrix metalloprotei-
nase (MMP) system [9]. The MMPs are a family of prote-
olytic enzymes that can cleave a large array of extracellular
matrix (ECM) proteins as well as other cellular, non-
matrix proteins. Particular MMPs (including MMP-2,
MMP-9 and MMP-14) are involved in key events in cancer
cells, including proliferation, apoptosis and angiogenesis
[10,11]. Importantly, loss of control of MMP activity has
been linked to the malignant potential of tumors by
enhancing invasion and metastasis [12]. When present in
sufficient amount, the tissue inhibitors of MMPs (TIMPs)
specifically inhibit MMP activity [11]. These interplay of
these molecules are critically important in tumor metasta-
sis.
Mutations in particular oncogenes and tumor suppressor
genes can promote cancer cell development and their
characteristic profile can help identify cancer cell types.
Mutations in the tumor suppressor phosphatase and
tensin homologue deleted on chromosome Ten (PTEN)
gene can been found in approximately 50% of endome-
trial cancer cells [13-15]. Mutation in both PTEN gene
alleles results in the expression of an inactive PTEN pro-
tein, which can not prevent activation of activated-by-
kinas-tyrosine protein also called Akt and results in con-
stitutively active Akt pathway. Since active Akt blocks the
action of several pro-apoptotic proteins [16], apoptosis is
deregulated in mutated PTEN cells. Mutational activation
of K-ras (Kirsten rat sarcoma) has been observed in 10–
30% of endometrioid carcinoma [17]. Ras is a signal
transducer located on the inner surface of the plasma
membrane. Hyperexpression of ras results in growth stim-
ulation, whereas point mutations at codons 12, 13, and
61 alter its structure, preventing inactivation and causing
cell transformation [18]. Amplification of Her-2/neu, a
proto-oncogene with a high degree of homology to the
epidermal growth factor (EGF), is associated with local
invasion and tumor progression of endometrial carci-
noma [19-22]. As these molecular alterations are hall-
marks of endometrioid cancers, their characterization in
cellular models is important. We had the opportunity to
characterize a new endometrial cell line that was recently
derived from an ovarian metastase, which represents a
putative new tool for the study of endometrial carcinoma
metastasis in vitro. We have extensively characterized this
cell line in term of growth and molecular properties.
Finally, deregulated apoptotic mechanisms that allow
cancer cell to proliferate and metastasize can lead to can-
cer cell resistance to pro-apoptotic agents such as chemo-
therapeutic drugs. We have characterized the response of
EN-1078D cells to the main chemotherapeutic agents cur-
rently used for the treatment of endometrial cancer, cispl-
atin and doxorubicin. Together, this information can be
applied to cellular and molecular studies in EN-1078D.
Methods
Patient data
The donor of the EN-1078D cell line was a 52-year-old
woman, gravida 1, para 1, menopaused since two years.
Histopathological examination revealed an endometrial
adenocarcinoma poorly differentiated stage IIIC, with
ovarian and ganglionic metastasis. At the time of surgery,
the advanced tumoral invasion of the uterus did not allow
its removal and bilateral ovariectomy was done. The
patient was initially treated with megestrol acetate (160
mg/day) associated with local radiotherapy (45 Gy) and
endocervical curietherapy. Six years after the initial sur-
gery, the patient is still alive without recurrence.
Histology of the original tissue and cell line establishment
The cell line was obtained from a patient of Centre Hospi-
talier de l'Université de Montréal and isolated from a
metastase which completely replaced the ovaries.
Informed consent was obtained and research studiesReproductive Biology and Endocrinology 2007, 5:38 http://www.rbej.com/content/5/1/38
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approved by the Montreal University Institutional Review
Board. The ovarian tumor consisted mainly of cells in
Indian file with some glandular structures and central
necrosis typical of an endometrial biopsy. At histopatho-
logical examination, immunohistochemistry analysis
revealed 80% positivity staining for oestrogenic receptors
and 25% for progesteronic receptors. Cells were estab-
lished in culture as described previously [23]. Briefly,
tumor tissue was minced with scissors into 2–4 mm
explants in OSE media (without Fetal Bovine Serum
(FBS)). Enzymatic dissociation was accomplished by
digestion with collagenase and aggregates were dissoci-
ated by gently pipetting. The cellular fraction was diluted
1:5 in OSE media supplemented with 10% v/v FBS and
incubated undisturbed at 37°C in 5% CO2/air for 24–48
hours. After cells had adhered to the plastic, they were
washed once in PBS and subsequently passaged in OSE/
10% v/v FBS until the cell line was stably established.
Afterwards, the cells were grown and maintained in
DMEM-F12 with HEPES (4-(2-hydroxyethyl)-1-pipera-
zineethanesulfonic acid), and the medium was supple-
mented with 10% v/v bovine growth serum (BGS) and 50
µg/ml gentamycin. Until now, the cell line was subcul-
tured more than a 100 passages and is preserved under
cryogenic conditions (5% v/v DMSO (dimethyl sulfox-
ide)/culture media, in liquid nitrogen). Experiments
using this cell line were carried out after long term passage
(>76 passages). For experimentation without steroid hor-
mones, the cell line was cultured at least two weeks in
phenol-free DMEM-F12 supplemented with 10% v/v dex-
tran-charcoal stripped FBS (FBS DC) and 50 µg/ml gen-
tamycin, prior experimentation.
Morphology of the cultured cells
Cells grown in culture flasks were photographed by phase-
contrast microscopy. For transmission electron micros-
copy study, the cells were grown to confluence in culture
flasks. They were washed with 0.1 M cacodylate buffer
(pH 7.4) and fixed with 2.5% v/v glutaraldehyde in
cacodylate buffer for 1 hour at room temperature. After
washing twice with buffer, the cell layer was delicately
detached with the help of cell scraper (Costar, VWR Can-
lab, Mississauga, ON, CA) and was postfixed with 1% v/v
osmic acid for 1 hour at room temperature. The cells were
then washed in cacodylate buffer, dehydrated in graded
concentrations of ethanol and embedded with Spurr over-
night. After polymerization, thin sections were contrasted
with 4% w/v uranyl acetate in 50% v/v methanol follow-
ing by lead citrate coloration. Specimens were examined
and photographed with a Phillips EM 208S electron
microscope.
In Vitro growth assays
Growth curves were performed by seeding cells (1 × 105)
into 42 flasks (25-cm2) in fresh culture medium (refer-
ence day 1). From day 2 to day 15, total cell numbers of 3
flasks were counted with a hemocytometer and discarded
thereafter [24]. The media was changed every 3 days. The
population doubling time was calculated from the slope
of the growth curve during the logarithmic phase while
saturation density was determined by the plateau phase.
For plating efficiency studies, one hundred cells were
plated in 100-mm petri dishes. After two weeks, the colo-
nies formed were fixed in 95% v/v ethanol and stained
with methylene blue. Plating efficiency was determined
by the ratio of the number of colonies (more than 50
cells) to the total number of inoculated cells [25]. The
experiments were done at each ten passages and were
repeated ten times.
In vivo growth assays
Subcutaneous tumor xenografts were established in four
6-week-old nude mice (Charles River Laboratories,
Lasalle, Qc, CA) by injection of 1 × 106 EN-1078D cells in
100 µL of 2 mg/mL Matrigel. (VWR, Mississauga, ON,
CA). The mice were injected at both flanks near the poste-
rior legs. The day following inoculation, mice received a
subcutaneous injection of 17 β-estradiol (E2) (0.15 mg/
animal in 5% cremophor and 5% ethanol saline solution)
to stimulate cell proliferation. Tumor size was measured
once a week using calipers. Tumor volume was calculated
using the formula 0.5 × length × (width)2 [26]. Eight
weeks after injection, mice were killed and tumors were
harvested. The tumors were fixed in 10% v/v formalin
solution and embedded in paraffin. Tumor sections (7
µm) were mounted on polylysine-coated slides, deparaffi-
nized, rehydrated, and then stained with haematoxylin.
Invasion assay
Cells were treated or not with Transforming growth factor-
beta3 (TGF-β3) (10 ng/ml) for 24 hours and then
trypsinised and washed in fresh media with serum. Cells
were then resuspended in media without serum and
counted. 3 × 104 cells were plated in a Transwell® Permea-
ble support (Costar 3432, Corning, USA) with a 8.0 µM
pore size polycarbonate membrane. Prior to cell plating, a
layer of BD Matrigel Low™, diluted 1:5 in fresh media
without serum was prepared and solidified. Fresh media
with 10% BGS was put in the well below the support.
Cells were cultured for 24 hours. At the end of the assay,
the cells which had adhered in the bottom of the well and/
or in filter were counted. These experiments were repeated
3 times.
Cytogenetic analysis
Repeated chromosome analyses were carried out at each
ten passages to examine the in vitro chromosomal evolu-
tion of this cell line. A total of 160 metaphases spreads
were photographed and the chromosome numbers in
each spread were counted. Harvesting, fixation, R and G-Reproductive Biology and Endocrinology 2007, 5:38 http://www.rbej.com/content/5/1/38
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banding of the chromosomes were induced by using clas-
sical techniques in cytogenetic. To confirm chromosome
X and copy number of the Her-2/neu gene, we performed
fluorescence in situ hybridization (FISH) with painting
probes CEP X (DXZ1)/Y (DYZ1) alpha satellite III and
Her-2 IVD Kit (Vysis/Abbott Laboratories, Mississauga,
ON, CA) according to the protocols supplied by the com-
pany and analyzed the karyotype with Cytovision.
MTT proliferation assays
For drugs assay, cells were plated at a density of 1.5 × 104
cells/well in 96-wells plates, 24 hours before the assay.
Cells were cultured for 24, 48 and 72 hours in the pres-
ence of increasing concentrations of cisplatin and doxoru-
bicin (0; 0.625; 1.25; 2.5; 5; 10 and 20 µM in DMF
(dimethylformamide)). HeLa, a cervical cancer cell line,
which we have previously found to be sensitive to these
drugs was used as positive control, while KLE, an endome-
trial adenocarcinoma cell line poorly inhibited by the
drug, was used as negative control. For steroid hormones
assays, cells cultured in phenol-free media were plated at
a density of 2 × 104cells/well in 96 wells plate, 24 hours
before the assay. Preliminary dose-response assays were
done to determine the treatments conditions: cells were
cultured for 48 hours with 10-6M of progesterone (P4) and
for 24 hours with 10-7M of E2, supplemented with 1%
FBD DC. At the end of the culture period, 10 µl of MTT (5
mg/ml, thiazolyl blue tetrazolium bromide) was added to
each well. After 4 hours of incubation with MTT, 100 µl of
solubilization solution was added (10% w/v SDS in 0.01
M HCl) and the microplate was incubated overnight
(37°C, 5% CO2/air). The OD (620 nm) was read with the
Fluostar Optima reader. The experiments were repeated 3
times.
Semi-quantitative RT-PCR analyses
In order to measure the presence or absence of transcripts
for keratins, oestrogen and progesterone receptors, vimen-
tin and desmin, semi-quantitative RT-PCR analyses were
performed. Primers (Invitrogen, Burlington, ON, CA)
chosen are described in Table 1. Conditions were opti-
mized by testing different primer concentrations and dif-
ferent number of cycles to avoid near-plateau or saturated
reactions. Total RNA (0.2 µg/µl) was used for preparation
of first strand cDNA by reverse transcriptase (RT). The
RNA samples were incubated (65°C, 10 min) with 2:1
oligo dT (deoxythymidine) primers in a final volume of
10:1. Samples were then incubated (37°C, 60 min) in
20:1 of a reaction buffer 10× containing dithiothreitol
(DTT, 100 mM), deoxynucleotide triphosphate (dNTPs, 5
mM) and Muloney Murine Leukemia Virus Reverse Tran-
scriptase (MMLV-RT, 200 U). The reaction volumes were
brought up to 60:1 with autoclaved water. A negative con-
trol was also included to control for contaminating
genomic DNA in the RNA template.
Each reaction mixture (final volume 50:1) contained 1×
Buffer, RT template or negative control (5:1), MgCl2 (50
mM), dNTPs (5 mM), primers (pM; 2,5:1 each) and Taq
polymerase (5 U/µl). The PCR cycling conditions chosen
were 30 sec at 94°C, 30 sec at the appropriate annealing
temperature and extension time at 72°C (Table 1), fol-
lowed by a 5 min extension at 72°C. Reaction products
were analysed on 1% w/v agarose gels. Bands were visual-
ized by ethidium bromide staining. β-actin was used as
loading control for each experiments.
Protein extraction and Western analysis
Cells were trypsinized, lysed in lysis buffer (PBS 1× pH
7.4; 1% Nonidet P-40; 0.5% Sodium deoxycholate; 0.1%
SDS; Protease Inhibitor Cocktail Tablets (Roche, Indiana-
polis, IN, USA), frozen and thawed three times, and cen-
trifuged (15,700 g, 20 min at 4°C) to remove insoluble
material. Supernatant was recovered and stored at -20°C
pending analysis. Protein content was determined with
the Bio-Rad DC Protein Assay (Bio Rad, Mississauga, ON,
CA). Protein extracts (50 µg except for cytokeratines where
25 µg was used) were heated (95°C, 3 min), resolved by
8, 10 or 14% w/v SDS-Polyacrylamide gel electrophoresis
(SDS-PAGE) and electro-transferred to nitrocellulose
membranes (15 V, 30 min) using a semi-dry transfer
apparatus (Bio-Rad). Membranes were then blocked (1
hr, RT) with PBS 1× containing 5% w/v non-fat milk pow-
der, and then incubated with primary antibody (ERα: Lab-
Vision Ab15, dilution1:500, positive control MS-1071-
PCL; ERβ: Labvision beta Ab-24 1:2000, positive control
RB-037-PCL; PRA-B: Cell Signaling #3172 dilution
1:1000; Pan-cytokeratins: Sigma c-2562, dilution
1:75000) overnight (except for β-actin, one hour) at 4°C,
and subsequently with Horseradish peroxidase (HRP)-
conjugated anti-rabbit secondary antibody (1:4000; RT,
45 min) or with HRP-conjugated anti-mouse secondary
antibody (1:2500; RT, 45 min). Peroxydase activity was
visualized with the Super Femto kit (Pierce/Fisher,
Nepean, ON, CA), according to the manufacturer's
instructions. β-actin was used as a loading control for each
experiments (Sigma A-3854 clone AC-15, dilution
1:60000, one hour).
Sequencing of the PTEN and K-ras genes
Mutation of the PTEN and K-ras gene at codons 12/13 and
61 respectively were examined by sequencing early pas-
sage EN-1078D. PTEN and K-ras gene were amplified by
PCR using the following primer pairs: for PTEN, 5'-CCCA-
GACATGACAGCCATC-3' (forward) and 5'-TTTCATGGT-
GTTTTATCCCTCTT-3' (reverse); for K-ras, 5'-
AGGCCTGCTGAAAATGACTG-3' (forward) and 5'-TCCT-
GAGCCTGTTTTGTGTCT-3' (reverse). An initial denatura-
tion of 3 min at 94°C was followed by 35 cycles of 30 sec
at 94°C, 30 sec at 58°C for K-ras/64°C for PTEN and 30
sec at 72°C for K-ras/1 min 30 for PTEN, and a final elon-R
e
p
r
o
d
u
c
t
i
v
e
 
B
i
o
l
o
g
y
 
a
n
d
 
E
n
d
o
c
r
i
n
o
l
o
g
y
 
2
0
0
7
,
 
5
:
3
8
h
t
t
p
:
/
/
w
w
w
.
r
b
e
j
.
c
o
m
/
c
o
n
t
e
n
t
/
5
/
1
/
3
8
P
a
g
e
 
5
 
o
f
 
1
4
(
p
a
g
e
 
n
u
m
b
e
r
 
n
o
t
 
f
o
r
 
c
i
t
a
t
i
o
n
 
p
u
r
p
o
s
e
s
)
Table 1: PCR primers, cycling conditions and positive controls used.
Primer Sens Primer Antisense Primer Size (bp)* annealing (celsius) cycles extension positive control
Keratin 1 5'-gatgaaggccacggtgatca-3' 5'-gacttgagttggggtgccta-3' 627 64 36 1 min KLE
Keratin 4 5'-ctccagcaaaaaccttgagc-3' 5'-aagtcattctcggctgctgt-3' 186 58 36 30 sec KLE
Keratin 5 5'-tctcgccagtcaagtgtgtc-3' 5'-atagccacccactccacaag-3' 247 58 36 30 sec KLE
Keratin 7 5'-caggatgtggtggaggactt-3' 5'-ttgctcatgtaggcagcatc-3' 116 58 30 30 sec KLE
Keratin 8 5'-agatgaaccggaacatcagc-3' 5'-tccagcagcttcctgtaggt-3' 262 58 30 30 sec KLE
Keratin 13 5'-gtcttcagcacccagaggag-3' 5'-ttgcagaaaggcaggaaact-3' 246 58 36 30 sec Hec-1-A
Keratin 18 5'-cacagtctgctgaggttgga-3' 5'-gagctgctccatctgtaggg-3' 164 58 36 30 sec KLE
Keratin 19 5'-tttgagacggaacaggctct-3' 5'-gccatgacctcatattggct-3' 275 58 30 30 sec KLE
Keratin 20 5'-acgccagaacaacgaatacc-3' 5'-acgaccttgccatccactac-3' 198 61 36 30 sec KLE
Vimentin 5'-gagaactttgccgttgaagc-3' 5'-tccagcagcttcctgtaggt-3' 170 58 36 30 sec KLE
Desmin 5'-caagctgcaggaggagattc-3' 5'-ggcagtgaggtctggcttag-3' 241 62 36 30 sec KLE
ER alpha 5'-gtgcctggctagagatcctg-3' 5'-agagacttcagggtgctgga-3' 265 66 36 30 sec MCF-7
ER beta 5'-tcaggcatgcgagtaacaag-3' 5'-gcttttactgtcctctgccg-3' 167 65 36 30 sec MCF-7
PR-A 5'-gcttcaagttagccaagaagagt-3' 5'-ctggaaattcaacactcagtg-3' 290 58 36 30 sec Ishikawa
PR-B 5'-acaccttgcctgaagtttcg-3' 5'-tccaagacactgtccagcag-3' 160 64 35 30 sec Ishikawa
MMP-2 5'-aggcaagtggtccgtgtgaa-3' 5'-acagtggacatggcggtctcag-3' 369 66 36 30 sec KLE
MMP-9 5'-caacatcacctattggatcc-3' 5'-cgggtgtagagtctctcgct-3' 479 60 36 30 sec KLE
MMP-14 5'-ccagggtctcaaatggcaaca-3' 5'-ccatggaagccctcggcaaa-3' 219 66 36 30 sec **
TIMP-1 5'-accagaccaccttataccagcg-3' 5'-ggactggaagcccttttcagag-3' 395 58 36 30 sec RL-95-2
TIMP-2 5'-atgcagatgtagtgatcagggc-3' 5'-gatgaagtcacagagggtgatg-3' 272 58 36 30 sec RL-95-2
β-actin 5'-gaggatcttcatgaggtagtctgtcaggtc-3' 5'-caactgggacgacatggagaagatctggca-3' 348 58 25 30 sec none
* Size of amplified fragment; ** PMA-treated THP-1 cellsReproductive Biology and Endocrinology 2007, 5:38 http://www.rbej.com/content/5/1/38
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gation step of 5 min at 72°C. PCR products were cloned
in competent E. coli using pcDNA3.1/V5-His TOPO TA
expression kit (Invitrogen, Burlington, On, Ca) according
to the manufacturer's instructions. For sequencing, PCR
products were purified with Miniprep purification kit
(Qiagen, Mississauga, ON, CA). The sequencing was car-
ried out using automatic sequencers models capillary ABI
PRISM 3100 and ABI PRISM 377 in the Laboratory of Syn-
thesis and Analysis of Nucleic Acids at Laval University
(Québec, QC).
Results
Cell morphology and growth
Early-passage EN-1078D was examined at low and high
resolution. Light microscopy revealed small, polygonal
cells organized in a pavement-like arrangement (Fig. 1A).
The cell line showed no contact inhibition and was char-
acterized by a tendency to pile up (Fig. 1B). The transmis-
sion electron microscopy revealed the presence of
numerous well-developed microvilli, intracytoplasmic
lipid droplets but no desmosomes (Fig. 1C). Only intri-
cate cytoplasmic interdigitations were observed (Fig. 1D).
To address the in vitro growth properties of EN-1078D,
cells were seeded into culture dishes and counted every 24
hours (Fig. 2). Results showed logarithmic growth for the
first 12 days, and we observed that cell growth continued
even when cells reached confluency and seemed limited
by the exhaustion of the culture media. Presence of float-
ing cells was noted from the day 12 of the experiment but
no layer of cells detached from the flasks even when cells
reached confluency. The plating efficiency increased
(89.5% to 98%) and the population doubling time
decreased (17.6 to 13.8 hours) with increasing number of
passages.
A) Phase contrast features of the monolayer-cultured EN-1078D cells revealing a sheet of polygonal cells with a pavement-like  arrangement Figure 1
A) Phase contrast features of the monolayer-cultured EN-1078D cells revealing a sheet of polygonal cells with a pavement-like 
arrangement. B) Transmission electron microscopy showing the tendency of cells to pile up. C) Ultrastructural aspects of EN-
1078D cell line by transmission electron microscopy. Cultured cells show a high nucleus-cytoplasmic ratio, euchromatic nuclei, 
prominent nucleoli and well-developed microvilli. D) Higher magnification shows intracytoplasmic lipid droplets (L), and exhib-
its intricate cytoplasmic interdigitations but no desmosomes were observed.
A A B B
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Molecular characterization of EN-1078D
To verify the epithelial origin of the cell line, we profiled
the expression of cytokeratins. RT-PCR (Reverse-tran-
scriptase polymerase chain reaction) revealed a predomi-
nance of the simple epithelial cytokeratins as indicated by
the presence of mRNA for cytokeratins 7, 8, 18 and 19
(Fig. 3A). Western Blot analysis confirmed the expression
of cytokeratins 18 and 19 (Fig. 3B); no suitable antibody
was available to confirm the expression of Ker7 and Ker8
proteins. Stratified-epithelial cytokeratin 5 mRNA was
also detected (Fig. 3A). We also examined the expression
of other intermediate filaments: as expected, the transcript
of a marker of muscle cells, desmin, was not detectable,
but mRNA from vimentin, which is overexpressed in can-
cerous cells, was present (Fig. 3A).
EN-1078D cells were also tested for the presence of estro-
gen and progesterone receptors. Figure 4A shows the hor-
monal receptor status of the cell line. RT-PCR and Western
Blot revealed the presence of both estrogen receptor alpha
and beta. Only low levels of PR-A mRNA and protein are
detectable although the EN-1078D cells expressed PR-B
mRNA and protein. In an attempt to determine if these
steroid hormones receptors were functional, we have sub-
jected EN-1078D cells treated with increasing concentra-
tions of 17β-estradiol and progesterone in phenol-free
conditions to MTT proliferation assay. Both estradiol and
progesterone could induce the proliferation of EN-1078D
cells (Fig. 4B and 4C). This indicates that these receptors
are functional in EN-1078D and also suggests that the
properties of these cells can be modulated by sex steroids.
In addition, we characterized the presence of chromo-
somal alterations in EN-1078D cells. Chromosome anal-
ysis revealed an aneuploid population with a complete
monosomy for the sexual chromosome X in more than
90% of the cells examined (45, X). The presence of a
minor population of cells was observed containing 46
chromosomes with a monosomy for the sexual chromo-
some and a trisomy for the chromosome 17 (46, X-X,
+17) (Fig. 5A). The proportion of this second population
varied with increasing number of cell passages, from 10%
at first passage to 48% after 20 passages.
To confirm the chromosomal complement 45, X, two
probes were used: CEP X (DXZ1) and Y (DYZ1) alpha sat-
ellite III. The DXZ1 probe, with an emission wavelenght
in the orange spectrum, hybridizes to the satellite DNA
localized in the centromere of the X chromosome, while
the DYZ1 probe, with an emission wavelenght in the
green spectrum, hybridizes to the satellite DNA III local-
ized in Yq12 locus (Fig. 5B). The results showed only one
positive signal in each 988 interphasic cells analyzed. No
green signal was obtained indicating that Y chromosome
Growth curves and characteristics of EN-1078D Figure 2
Growth curves and characteristics of EN-1078D.
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was not present. Figure 5C shows an interphasic hybridi-
zation carried out with a probe located on the long arm of
chromosome 17q11.2q12 called Her-2/neu. To deter-
mine the number of copies of the Her-2/neu gene present
in this cancer cell line, we used a probe marked with a flu-
orescent protein emitting in the orange spectrum which
covers the complete Her-2/neu gene as well as a probe
marked with fluorescent protein emitting in the green
spectrum hybridizing to the satellite DNA in the centro-
mere of chromosome 17. The analysis of 1000 cells
showed that only one copy of this gene was present in
chromosome 17, indicating no amplification of Her-2/
neu gene in EN-1078D cells: a low level of amplification
range is between 2 and 4 signals/centromere [27]. We
have found, however, other types of mutations in this cell
line: sequencing revealed two sites of mutations in PTEN
gene. Codon 275 is mutated by addition of a nucleotide
and codon 367 replaces a valin for isoleucin. In addition,
K-Ras gene analysis showed the classical G to T transver-
sions in the codon 12 (data not shown).
Chemosensitivity of EN-1078D cell line
We have examined the resistance of EN-1078D to two
chemotherapeutic agents currently used for the treatment
of endometrial carcinoma, cisplatin and doxorubicin,
using the MTT proliferation assay. Two other cell lines
were used as a reference: HeLa, a cervical cancer cell line
that we showed to be sensitive to these anticancer agents,
and KLE, an endometrial cancer cell line known to be
chemoresistant [28]. Even after a short exposure of 24
hours to cisplatin, EN-1078D cells were more sensitive
than both Hela and KLE (Fig. 6A–C). EN-1078D cells
reached IC50 at 2.8 µM of cisplatin after 72 hours of expo-
sure comparatively at 6.7 µM for HeLa while KLE cells
showed 30% of growth-inhibition in the same condi-
tions. In the case of doxorubicin, 48 h of exposure were
required for EN-1078D cells to be growth-inhibited and
reached IC50 to 0.5 µM of this compound; HeLa and KLE
cells were more resistant to the effects of doxorubicin than
EN-1078D cells (Fig. 6D–F) with a IC50 of 0.6 µM for
HeLa after 48 hours of exposition and for 1.4 µM for KLE
after 72 hours. Altogether these results indicate that EN-
1078D cells are sensitive to the cytotoxicity of cisplatin
and doxorubicin (Fig. 6F).
In order to test the tumorigenic potential of EN-1078D in
vivo, we performed subcutaneous xenograft experiments
in nude mice. All mice developed palpable tumors, and
Expression of cytokeratins in EN-1078D Figure 3
Expression of cytokeratins in EN-1078D. A) RT-PCR analysis for stratified-, simple-epithelial cytokeratins and for the other 
types of intermediate filaments. In EN-1078D cells, the simple-epithelial cytokeratins are predominantly expressed. Vimentin 
expression is consistent with the neoplasic tissue while absence of the expression of desmin confirmed that EN-1078D is not 
an endometrial sarcoma. B) Expression of cytokeratins 18 and 19 by Western Blot analysis KLE was used like as positive con-
trol Data shown are representative of results obtained from three independent assays.
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A) Karyotype analysis of EN-1078D (P76+13 passages),  showing that all cells have monosomy of X chromosome Figure 5
A) Karyotype analysis of EN-1078D (P76+13 passages), 
showing that all cells have monosomy of X chromosome. 
Most of the cells have trisomy of chromosome 17. B) FISH 
analysis of copy number of X chromosome with Probe CEP 
X (DXZ1) alpha satellite III. Probe DXZ1 marked in orange 
spectrum hybrid satellite DNA localized in the centromere 
of the X chromosome. Only one X chromosome per cell 
was observed. C) Metaphasic analysis of Her2/neu (human 
epidermal growth factor receptor 2) by fluorescence in situ 
hybridization (FISH). The HER-2 probe spans the entire HER-
2 gene is labeled in spectrum orange. The CEP 17 probe is 
labeled in spectrum green and hybridizes to the alpha satellite 
DNA located at the centromere of chromosome 17 
(17p11.1-q11.1). Inclusion of the CEP 17 probe allows for the 
relative copy number of the HER-2 gene to be determined.
A
B
C
Sex steroid receptor status Figure 4
Sex steroid receptor status. A) Both estrogen and progester-
one receptors mRNA are detected by RT-PCR but the signal 
for PR-A is very weak and protein is not detected by West-
ern blot analysis. Ishikawa cell line was used as a positive con-
trol for PRA-B antibody. Data shown are representative of 
results obtained from three independent assays. MTT prolif-
eration assay was conducted to verify the functionality of 
these receptors in EN-1078D cell line: B) 24 hours of expo-
sure to 17β-oestradiol increases cell growth and C) a signifi-
cant increase in proliferation was observed after 48 hours of 
exposure to 10-6M for progesterone (p < 0.05). Data shown 
are representative of results obtained from three independ-
ent assays.
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about 8 weeks after inoculation, the tumor size had
reached a volume of 350 mm3 or more (Fig. 7A). The
encapsulated tumors were compact in periphery with a
liquefied center. Histologic analysis of tumors showed no
specific organisation pattern of tumor cells nor observable
structures like basal lamina (Fig. 7B). These results indi-
cate that EN-1078D cells are tumorigenic and can there-
fore be used for in vivo tumor growth experiments. No
macroscopic metastases were visible in spleen, lungs or
liver up to eight weeks post-xenograft. On the other hand,
EN-1078D showed 2 fold increase of total number of the
invasive cells when the cells were treated with TGF-β3[29]
Determination of EN-1078D sensitivity to cisplatin (left panel) and doxorubicin (right panel) Figure 6
Determination of EN-1078D sensitivity to cisplatin (left panel) and doxorubicin (right panel). A, D) 24 hours of exposure to 
compounds B, E) 48 hours and C, F) 72 hours. Both Hela and EN-1078D are sensitive to cisplatin after 24 hours in contrast to 
KLE, which is chemoresistant. The three cell lines seem not to be affected by doxorubicin after exposure of 24 hours. KLE is 
more resistant than other cells lines for both 48 and 72 hours. Data shown are representative of results obtained from three 
independent assays.
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(fig. 8A) after 24 hours of invasion assays. Together, these
results confirm that EN-1078D cells constitute an excel-
lent in vitro model to characterize the molecular and cellu-
lar mechanisms involved in the invasive phenotype of
endometrial carcinoma cells.
Constitutive expression and activity of MMPs increases
the invasiveness of various types of cancer cells, and we
have determined characterized the expression of MMP-2,
MMP-9 and MMP-14 as well as TIMP-1 and TIMP-2
mRNA in EN-1078D cells, using RT-PCR (Fig. 8A and 8B).
We found elevated levels of MMP-2 and its physiological
activator, MMP-14 mRNAs (Fig. 8B), and low levels of
their inhibitor TIMP-2 mRNA (Fig. 8C). As expected, we
found that MMP-9 mRNA was not expressed constitu-
tively (Fig. 8A), suggesting that external stimuli, such as
contact with matrix protein in Matrigel, for instance, are
required to induce the expression of the enzyme. Low lev-
els of TIMP-1 transcript were found in EN-1078D cells
(Fig. 8C).
Discussion
The present study describes the characterization of a new
poorly differentiated endometrial carcinoma cell line, EN-
1078D, isolated from a metastasis to the ovary. Although
many endometrial carcinoma cell line have demonstrated
their capacities to form tumors and/or metastases in nude
mice (Hec-1-A, Hec-1-B, RL-95-2 and Ishikawa) [30-32],
only few endometrial cancer cell lines derived directly
from metastatic cancer cells (AN3CA and KLE) [33,34].
We have confirmed the origin of simple epithelial cells
[35] for this cell line and the endometrial carcinoma phe-
notype of the metastatic tumor cells because the EN-
1078D cell line was isolated from a ovary. In addition,
EN-1078D analysis revealed the presence of two cell pop-
ulations in this cell line which is often the case in cultures
derived from tissues. The presence of only one chromo-
some X in both populations of EN-1078D cell line con-
firmed the same origin for these two populations. The
differentiation in two types of cell populations by the
achievement of the third chromosome 17 was the fact of
malignant transformation which seems to give an advan-
tage for in vitro growth to this cellular population com-
pared to the other one [36,37]. In addition, we have tested
the response of EN-1078D cells to two chemotherapeutic
Invasion assay and expression of MMPs and TIMPs mRNA in  EN-1078D Figure 8
Invasion assay and expression of MMPs and TIMPs mRNA in 
EN-1078D. A) EN-1078D cells showed capacities to increase 
their invasiveness by 2 fold induction when they were stimu-
lated with TGF-β3. B) The cell line expresses MMP-2 and 14 
while MMP-9 was not detected. The signal for MMP-2 is 
stronger for EN-1078D cells than for the positive control 
used. C) Both TIMPs expressions were detected but TIMP-2 
signal is weak. Data shown are representative of results 
obtained from three independent assays.
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A) Tumorigenicity of EN-1078D cells in nude mice. B) Histol-
ogy of subcutaneous tumor taken from nude mice showed 
large solid masses composed of poorly differentiated carci-
noma cells with no apparent structures (haematoxylin, 40×)
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agents commonly used: cisplatin and doxorubicin. In fact,
with his high FIGO (International Federation of Gynecol-
ogy and Obstetrics) grade (III), his poor differentiation
and his aggressiveness, it is surprising that this cell line is
so sensitive to these compounds. It is suggested that the
karyotypes of the cultured cells may undergo considerable
changes in vitro and some of these changes may represent
the malignant transformation process of the tumor cells in
vivo [35,36].
Sex steroid receptors status is crucial in the development
of endometrial cancer. EN-1078D cells show all func-
tional sex steroid receptors except for PR-A, which is not
expressed. Expression of PR-B alone, a strong regulator of
proliferation [8,38], is only seen in tumor cells [39] and
was a feature of high-grade tumors. A study by Fujimoto
and Ichigo [40] has reported that in all metastatic lesions
of uterine endometrial cancers, the expression of PR-A
mRNA was suppressed and PR-B mRNA was dominantly
expressed which are in correlation with our observations.
Additionally, the presence of the both ERα and ERβ in EN-
1078D cells confirm that this cell line will become a very
interesting tool of study because the majority of endome-
trial cancer cell lines available express only one of these
two receptors.
Loss of progesterone responsiveness in endometrial can-
cer [41] combined with the expression of some MMPs
might be related to the metastatic potential of EN-1078D
cells. The level expression of MMP-2, MMP-14 and TIMP-
2 in EN-1078D cell line is consistent with an endometrial
cancer with high invasive potential [42]. The team of
Graesslin [43] has found a relation between low TIMP-2
expression and myometrial invasion, lymphovascular
space involvement, and lymph node metastasis. MMP-9 is
normally induced under conditions that require tissue
remodelling [44] and is predominantly expressed by
inflammatory cells of the stroma [45]. EN-1078D cells do
not express MMP-9 in basal and normal culture condi-
tions but they may produce the enzyme in other, more
physiological, conditions. Given that this cell line express
constitutive levels of MMP-2 and MMP-14, and that EN-
1078D cells were highly invasive in vitro, this cell line rep-
resent an important tool for the characterization and the
study of the molecular and cellular mechanisms regulat-
ing endometrial carcinoma cell invasion.
In endometrial cancers, frequents lesions were observed
including K-Ras and PTEN mutations and Her-2/neu
amplification [46]. Our finding that K-Ras is mutated in
EN-1078D cell line is supported by many studies suggest-
ing that the majority of mutations present in the codon 12
of K-Ras and G to T transversions were predominating in
the North American population [47]. Mutations of the
Ras oncogene results in autonomous cell growth [48] by
enhancing estrogen and antiestrogen (tamoxifen)-
induced transcriptional activity of the ER activation func-
tion [49,50]. A significant correlation was found between
ER-dependent PR expression and activating K-Ras muta-
tions suggesting that enhanced activity of the ER activa-
tion function by stimulating phosphorylation mediated
through mutational activation of the Ras-MAPK cascade
may be one mechanism of hormone independence of
endometrial cancer [51].
PTEN gene is frequently mutated in endometrial cancer.
We have identified to 2 sites of mutations in EN-1078D
cells affecting the C-terminal domain. This domain, in
which ≥ 43% of PTEN mutations occur, contains many
important subdomains that are common to other signal-
transducing molecules [52]. The C2 domain (amino acids
186–351) is associated with phospholipids-binding
regions [53] and has been identified in many proteins
involved in signal transduction and membrane localiza-
tion [54]. The C-terminal tail also contains a sequence
rich in proline, glutamic acid, serine and threonine (PEST
sequence) (amino acids 350–375 and 379–396), which
are critical for PTEN stability [55]. PEST sequences target
proteins for short intracellular half-lives and protein deg-
radation. Paradoxically, deletion of these regions leads to
decreased protein expression versus the expected increase.
Nonetheless, these studies point out that the PEST regions
are necessary for PTEN stability and in EN-1078D cell line
the PEST region contains one mutation. PTEN antago-
nizes the PI3K/Akt pathway by dephosphorylating
PIP3(Phosphatidylinositol (3,4,5)-trisphosphate), result-
ing in a decreased translocation of Akt to cellular mem-
branes and subsequent down-regulation of Akt activation.
It has been shown that expression of PTEN in cells leads
to decreased levels of phospho-Akt (active form), and,
therefore, to increased apoptosis [56,57]. For example,
RL-95-2 and Ishikawa endometrial cancer cells lines have
a mutation in the PTEN gene and express high levels of
phospho-Akt [58-60]. However, the mutated PTEN-cell
line EN-1078D express weak levels of phospho-Akt (data
not shown) which suggests that the simple mutation of
PTEN in this cell line is not sufficient to induce constitu-
tive Akt phosphorylation.
In conclusion, our results suggest that EN-1078D cell line
is an endometrial carcinoma originating from simple epi-
thelial cells. This tumorigenic cell line, positive for both
estrogen receptor isoforms and progesterone receptor B,
presents mutations in PTEN and K-Ras genes, one tumor
suppressor and one oncogene frequently mutated in
endometrial cancers. Moreover, EN-1078D expresses high
level of MMP-2, no MMP-9 and a weak expression of
TIMP-2. These cells express weak levels of phosphorylated
Akt and show sensitivity to drugs commonly used in
chemotherapy. EN-1078D cell line showed tumorigenicReproductive Biology and Endocrinology 2007, 5:38 http://www.rbej.com/content/5/1/38
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capacities in vivo and is a very aggressive cell line with high
invasiveness in vitro. EN-1078D will be a useful tool to
study the mechanisms involved in the invasion of
endometrial cancer cells, and their regulation by sex ster-
oids.
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